New Chemical Entities from Nature: Selection and Valorization in Oncology, from New Patents to Clinical PhaseBased on the Research performed in Universities and patents recently filed and obtained, OnCoBel s.a. will only select First-in-Class (FIC) compounds on the basis of Mode of Action in order to enter into Pre-Clinical Development and further Clinical Phase development.Key Facts & Strategic VisionDrug discovery efforts are supported by in-licensed research programs from Academia, with COG's taken very early in the screening process. First in Class compounds (based on Mode of Action) will enter Pre-Clinical Development è competitive out-licensing process as early as Phase I.A Team of renowned Oncology and Development specialistsOnCoBel s.a. has been founded by Prof. R. Kiss, R. Director at the FNRS, by Jo Gottal of the WR Wood Institute, including pharma exploitation from Belgian forest, helped by several University Professors and Finance people. Dr Kiss is a world renowned cancer specialist who identified the Vinflumine as well as molecules having completed theirs Ph. I/II. He has authored or coauthored 32 Patents and 420 publications in Cancer. Prof. Michel Deleers, previously VP Pharmaceutical Devs at UCB Pharma joined them as CEO. M Deleers has authored or coauthored 21 Patents and 90 publications, mainly in formulations, route of synthesis and DDS.OnCoBel s.a. has a pipeline of 6 NCE's.